Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
| Revenue (TTM) | $327.80B |
| Gross Profit (TTM) | $272.72B |
| EBITDA | $173.88B |
| Operating Margin | 61.60% |
| Return on Equity | 71.40% |
| Return on Assets | 19.30% |
| Revenue/Share (TTM) | $73.77 |
| Book Value | $6.96 |
| Price-to-Book | 6.96 |
| Price-to-Sales (TTM) | 0.67 |
| EV/Revenue | 4.706 |
| EV/EBITDA | 8.58 |
| Quarterly Earnings Growth (YoY) | 67.10% |
| Quarterly Revenue Growth (YoY) | 24.00% |
| Shares Outstanding | $3.35B |
| Float | $3.18B |
| % Insiders | 0.01% |
| % Institutions | 9.93% |
Volatility is currently expanding
Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.
Novo Nordisk (NVO) is rated a Modest Buy with a raised price target of $80, driven by oral Wegovy's rapid market adoption. Oral Wegovy has achieved over 3 million prescriptions in five months, with 80% from GLP-1–naïve patients, expanding the addressable market. Sensitivity analysis suggests a base case wherein oral Wegovy could generate $12–$15 billion in annual gross profit under realistic assumptions.
Novo Nordisk (NVO) has experienced a 30%+ stock decline since mid-2024, extending its ongoing downtrend. Novo Nordisk reports Q2 results next week, with investors focused less on near-term beats and more on management's confidence in transformation plans. Oral Wegovy has rapidly gained prescriptions, attracting predominantly new GLP-1 patients and expanding Novo's addressable market without materially cannibalizing established treatments.
I initiate Novo Nordisk with a BUY rating and $68 price target, viewing current valuation as an attractive entry point. Oral Wegovy is expanding the treated obesity market, not just cannibalizing injectables, supported by strong prescription growth and efficacy data. Pipeline assets like high-dose Wegovy, CagriSema, and Zenagamtide offer risk-adjusted lifecycle support but face efficacy and tolerability challenges.
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.
Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry between the two groups.
MCLEAN, Va.--(BUSINESS WIRE)--Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healthcare company Novo Nordisk to expand affordable and simplified access to authentic anti-obesity medications (AOMs) like Wegovy® for employer health plans across the United States. Through an alternative pharmacy benefit structure, the agreement will allow Crux to deliver a dedicated carve-out solut.
Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.
The polite duopoly running the modern weight-loss drug boom just filed for divorce, and the market voted before the ink dried.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVO and any ticker you trade — then tracks every position and per-strategy win rate.
